A series of 2-amino-4H-3,1-benzoxazin-4-ones have been synthesized and
evaluated as inhibitors of the complement enzyme C1r. C1r is a serine
protease at the beginning of the complement cascade, and complement a
ctivation by beta-amyloid may represent a major contributing pathway t
o the neuropathology of Alzheimer's disease. Compounds such as ro-2-[(
2-iodophenyl)amino]benz[d][1,3]oxazin-4-one (32) and 7-methyl-2-[(2-io
dophenyl)amino]benz[d] 4-one (37) show improved potency compared to th
e reference compound FUT-175. Many of these active compounds also poss
ess increased selectivity for C1r compared to trypsin and enhanced hyd
rolytic stability relative to 2-(2-iodophenyl)-4H-3,1-benzoxazin-4-one
(1).